The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic malignant pleural mesothelioma (download slides below). This marks the first new treatment for mesothelioma in over 15 years, providing a new option for patients battling this aggressive disease. Key Results from the KEYNOTE-483 Trial The … Continue reading FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES